By Gina Shaw
The FDA has granted breakthrough therapy designation for Genentech’s drug ocrelizumab in patients with primary-progressive multiple sclerosis (PPMS). 
ms.gif" height="300" width="300" />
Ocrelizumab is the first investigational MS compound to earn the breakthrough designation, which expedites the development and review of drugs intended to treat serious or life-threatening diseases. There are no FDA-approved treatments for PPMS, which affects about 10% of the